fbpx
QQQ
-4.14
343.48
-1.22%
DIA
-3.14
344.38
-0.92%
SPY
-3.82
419.91
-0.92%
TLT
+ 0.61
139.17
+ 0.44%
GLD
-1.06
169.18
-0.63%

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates

by
March 20, 2014 4:29 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year.

Trinity Biotech plc (NASDAQ: TRIB) is likely to earn $1.16 per share in the next year ending December, 2015. Trinity Biotech’s trailing-twelve-month operating margin is 18.98%.

Meridian Bioscience (NASDAQ: VIVO) may earn $1.07 per share in the next year ending September, 2015. Meridian Bioscience’s PEG ratio is 2.19.

SurModics (NASDAQ: SRDX) is projected to earn $1.01 per share for the next year ending September, 2015. SurModics’ trailing-twelve-month revenue is $56.16 million.

Neogen (NASDAQ: NEOG) is expected to earn $0.94 per share over the next year ending May, 2015. Neogen’s trailing-twelve-month ROE is 10.59%.

Posted-In:

Trading Ideas

Related Articles

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI